These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32589926)

  • 81. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
    Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
    Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
    Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
    J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
    [TBL] [Abstract][Full Text] [Related]  

  • 83. SERS-active liposome@Ag/Au nanocomposite for NIR light-driven drug release.
    Zhao Y; Zhao J; Shan G; Yan D; Chen Y; Liu Y
    Colloids Surf B Biointerfaces; 2017 Jun; 154():150-159. PubMed ID: 28334692
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ramizol
    Wright L; Rao S; Thomas N; Boulos RA; Prestidge CA
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1451-1457. PubMed ID: 29619851
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
    Wicki A; Ritschard R; Loesch U; Deuster S; Rochlitz C; Mamot C
    Int J Pharm; 2015 Apr; 484(1-2):8-15. PubMed ID: 25701632
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reduction/pH dual-sensitive PEGylated hyaluronan nanoparticles for targeted doxorubicin delivery.
    Xu M; Qian J; Suo A; Wang H; Yong X; Liu X; Liu R
    Carbohydr Polym; 2013 Oct; 98(1):181-8. PubMed ID: 23987334
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A Simple and Easy Method of Monitoring Doxorubicin Release from a Liposomal Drug Formulation in the Serum Using Fluorescence Spectroscopy.
    Watanabe A; Murayama S; Karasawa K; Yamamoto E; Morikawa S; Takita R; Murata S; Kato M
    Chem Pharm Bull (Tokyo); 2019; 67(4):367-371. PubMed ID: 30930441
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Bioreducible Poly(ethylene glycol)-Triphenylphosphonium Conjugate as a Bioactivable Mitochondria-Targeting Nanocarrier.
    Khatun Z; Choi YS; Kim YG; Yoon K; Nurunnabi M; Li L; Lee E; Kang HC; Huh KM
    Biomacromolecules; 2017 Apr; 18(4):1074-1085. PubMed ID: 28257184
    [TBL] [Abstract][Full Text] [Related]  

  • 90. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
    Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
    Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
    [TBL] [Abstract][Full Text] [Related]  

  • 91. In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B: A biorelevant and clinically relevant approach.
    Díaz de León-Ortega R; D'Arcy DM; Lamprou DA; Xue WF; Fotaki N
    Eur J Pharm Biopharm; 2021 Feb; 159():188-197. PubMed ID: 32717384
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.
    Nagpal S; Png Yi Jie J; Malinovskaya J; Kovshova T; Jain P; Naik S; Khopade A; Bhowmick S; Shahi P; Chakra A; Bhokari A; Shah V; Gelperina S; Wacker MG
    ACS Nano; 2024 Feb; 18(8):6162-6175. PubMed ID: 38359902
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin.
    Li Z; Kovshova T; Malinovskaya J; Knoll J; Shanehsazzadeh S; Osipova N; Chernysheva A; Melnikov P; Gelperina S; Wacker MG
    Int J Nanomedicine; 2024; 19():2039-2056. PubMed ID: 38476274
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin.
    Gan K; Li Z; Darli PM; Wong T; Modh H; Gottier P; Halbherr S; Wacker MG
    Int J Pharm; 2024 Apr; 654():123942. PubMed ID: 38403086
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations.
    Osipova N; Budko A; Maksimenko O; Shipulo E; Vanchugova L; Chen W; Gelperina S; Wacker MG
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111743
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
    Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
    Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.
    Toley BJ; Tropeano Lovatt ZG; Harrington JL; Forbes NS
    Integr Biol (Camb); 2013 Sep; 5(9):1184-96. PubMed ID: 23860772
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Distinguishing Pharmacokinetics of Marketed Nanomedicine Formulations Using a Stable Isotope Tracer Assay.
    Skoczen SL; Snapp KS; Crist RM; Kozak D; Jiang X; Liu H; Stern ST
    ACS Pharmacol Transl Sci; 2020 Jun; 3(3):547-558. PubMed ID: 32566919
    [TBL] [Abstract][Full Text] [Related]  

  • 99. In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling.
    Díaz de León-Ortega R; D'Arcy DM; Lamprou DA; Fotaki N
    Eur J Pharm Biopharm; 2020 Mar; ():177-187. PubMed ID: 32147578
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Building Blocks to Design Liposomal Delivery Systems.
    Juszkiewicz K; Sikorski AF; Czogalla A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33334048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.